Tests used for neuromuscular patients in the clinic need validating for home use

The COVID-19 pandemic has provided an impetus to examine the feasibility of collecting clinical outcome assessments (COAs) in the patient’s home to permit continuity of clinical trial data as well as clinical care. But many COAs require validation and likely some modifications from the original in order to be used remotely, according to a consensus group.

At WMS 2021, Dr Linda Lowes, Nationwide Children’s Hospital, Center for Gene Therapy, Columbus, OH, USA, presented findings from the TREAT-NMD remote outcome measures group.